Summit Schedule

The 9th Annual California ALS Research Summit will be held at the Arnold and Mabel Beckman Center of the National Academies of Sciences and Engineering - 100 Academy, Irvine, CA 92617. Please be sure to register in advance for the summit.
 
This year’s agenda will be organized around specific themes that are relevant to the consortium as basic science and/or clinical topics.  Each theme will be initiated by a platform talk (30-40 min) followed by an open panel discussion (60 min or more).  The panel will be provided several points to trigger discussion with the expectation of a dialogue between attendees and the panel.  
 


Preliminary agenda



 THE 9th Annual California ALS Research NETWORK SUMMIT

Friday, January 11 – Saturday, January 12 , 2019 – Beckman National Academy of Science Building


 

 DAY 1:                  Friday, January 11, 2018 


Arnold and Mabel Beckman Center of the National Academies of Sciences and Engineering

100 Academy Way, Irvine, CA 92617

 

7:45 – 8:10 a.m.        Registration, Poster Session and Breakfast

                

8:10 – 8:20 a.m.        Welcome to Irvine, Conference Overview

        • Fred Fischer and Lucie Bruijn, PhD, The ALS Association
        • Leslie Thompson, PhD, Local organizer UC Irvine
        • Clive Svendsen, PhD, Chair, California ALS Research Network; Director, RMI, Cedars-Sinai Medical Center

8:20 – 9:00 a.m.     Keynote Lecture: Inflammation and neurodegenerative diseases  Len Petrucelli                                  

 

9:00 – 10:00 a.m.       Theme I:  Inflammation and ALS (15 Minutes Each + 5 Min Questions)

        • (Microglia and neurodegeneration/new animal models of AD) – Kim Green, PhD, Associate Professor and Vice Chair, Neurobiology and Behavior, UC Irvine
        • iPSC-derived microglia – Mathew Blurton-Jones, PhD, Associate Professor, Neurobiology and Behavior, UC Irvine
        • TBA – Robert Baloh, MD, PhD, Ben Winters Chair in Regenerative Medicine, Director of Neuromuscular Medicine, and Professor of Neurology and Biomedical Sciences, Cedars-Sinai

                                                 

10:00 – 10:20 a.m.       Discussion 

 

10:20 – 10:40 a.m.    Break and Posters


10:40 – 11:40 a.m.   Clinical Trials – (10 Minutes Each)
        • ALSA Accelerator Fund   Lucie Bruijn, PhD, ALSA and Fred Fisher, ALSA
        • TBD – Alan Kleinfield
        • Biogen C9 trial – Toby Ferguson, MD
        • Avexis SOD1 trial Gretchen Thomsen, PhD, Cedars Sinai/Kaspar

11:40 – 12:00 p.m.    Discussion 

 

12:00 – 12:30 p.m.       Lunch


12:30 – 1:30 p.m.    Poster Session


1:30 – 2:10 p.m.      Theme II:  Stem cell trials for ALS (15 Minutes Each + 5 Minute Questions)

   
      • Update on Brainstorm Trial – Ralph Kern, MD, MHSC, Chief Operating Officer and Chief Medical Officer, Brainstorm Cell Therapeutics 
      • Update on Cedars-Sinai GDNF Trial – Clive Svendsen, PhD Cedars-Sinai Medical Center
         


  • 2:10 – 2:20 p.m.      Discussion


    2:20 – 3:20 p.m.     Theme III ALS mechanisms and RNA splicing

     

          • TBD – Aaron Gitler, PhD, Professor of Genetics, Stanford University 
          • TBD – Don Cleveland, PhD, Chair, Department of Cellular and Molecular Medicine, and Professor of Medicine, Neurosciences and Cellular and Molecular Medicine, UCSD
          • Potential of Applying Chemical Tools to Study RNA in ALS  –  Rob Spitale, PhD, Chancellor’s Fellow and Associate Professor of Pharmaceutical Sciences, UC Irvine – RNA boil     
          • RNA splicing considerations lessons from SMA Klemens Hertel, PhD, Professor and Vice Chair, Microbiology and Molecular Genetics, UC Irvine                               

     

    3:00 – 3:20 p.m.       Discussion




  •                                   

    3:20 – 3:50 p.m.          Break – Poster Break Down

     

    3:50 – 4:30 p.m.       Student/Post-Doc Data Blitz – to be chosen from posters… 

     

    4:30 – 5:10 p.m.       Updates from Industry (10 Minutes Each)

     

          • Denali Joe Lewcock, PhD, Head of Biology Discovery, Denali Therapeutics
          • Cytokinetics – Andy Wolff, MD, FACC, SVP and Chief Medical Officer
          • Ionis Pharmaceuticals – Frank Rigo, PhD

     

    5:10 – 5:30 p.m.       Discussion

     

     

    6:30 – 7:00 p.m.        Cocktail Reception Sponsored by Duane Morris LLP

                                        

     

    7:00 – 8:00 p.m.         Dinner

     

    Welcome Remarks – Fred Fisher, MSW, LCSW, President & CEO, ALS Association Golden West Chapter 

     

    The Jim Barber poster award winner announcement and presentation

     

                                       "Update on right to try" – Ryan Smith, PhD??, Associate, Duane Morris LLP (10 min)

     

     

          



    DAY 2:              Saturday, January 12, 2018

    Tamkin Student Lecture Building at the UC Irvine School of Medicine

    Health Sciences Road, Irvine, CA 92697

    7:45 – 8:15 a.m.         Breakfast

    8:15 – 9:15 a.m.         Theme IV: New technologies relevant to ALS (15 Minutes Each + 5 Minute Questions)

     

          • A new approach for three dimensional modeling of RNA/DNA - Mitch Guttman, PhD, Assistant Professor, Division of Biology and Biological Engineering, Caltech –

     

          • Answer ALS – Leslie Thompson, Steve Finkbeiner, PhD, UC Irvine UCSF – Answer ALS

     

          • AI and machine learning in imaging – Daniel Chow, PhD, Assistant Professor in Residence, Radiological Sciences –  Peter Chang, PhD, Assistant Professor in Residence, Radiological Sciences, UC Irvine

     

    9:15-9:45 a.m.       Discussion

    9:45 – 10:00 a.m.          Break

     

    10:00 – 10:40 a.m.    Theme V: New approaches for ALS (15 Minutes Each + 5 Minute Questions)


          • The Lazarus Project: Resurrection of the Neuromuscular Junction after Traumatic Nerve Injury Ranjan Gupta, MD, Professor and Chair, Orthopaedic Surgery, UC Irvine  


          • Sue and Bill Gross Stem Cell Research Center, and Professor, Physical Medicine & Rehabilitation, UC Irvine, neuroinflammation –  Aileen Anderson, PhD, Director

    10:40 – 11:00 a.m.   Discussion


    11:00 – 11:30 a.m.      Updates from Industry II (10 Minutes Each)


          • Genentech – Arundhati Sengupta Ghosh, Senior Research Associate       
          • Mallinckrodt – Patrice Becker, MD, Vice President, Medicines Team Lead Autoimmune & Rare Diseases
          • BioGen – Toby Ferguson, MD, Senior Medical Director


    11:30 – 12:00 p.m.   Discussion   

    12:00 – 1:00 p.m.             Lunch

    1:00 – 1:30 p.m.            The Neurocollaborative   Svendsen, Finkbeiner, Cleveland, Kaspar,

     

    1:30 – 2:30 p.m.      Theme V: Clinical Challenges in ALS this can be transition to John session.  

    Global challenges for designing clinical trials in ALS

            • Promising Outcome Measures for Phase 2 Trials – Jeremy Shefner
            • ATLAS as an outcome measure – Peggy Allred
            • Improving patient recruitment across sites in CA
            •  John Ravits

     

    2:30 – 2:45 p.m.             Break

    2:45 – 3:45 p.m.       Clinical challenges continued…..

     

     

    3:45 – 4:00 p.m.        Final comments

                                    Lucie Bruijn, PhD, Clive Svendsen, PhD

     

    4:30 – 6:00 p.m .  Research update to ALS community – all participants welcome



    Comments